Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoko Kanda

Showing results (41-50 of 183) with videos related to

Pageof 19
Sort By:
International Journal of Molecular Sciences|September 25, 2019
The Roles of Sex Hormones in the Course of Atopic DermatitisNaoko Kanda, Toshihiko Hoashi, Hidehisa Saeki
International Journal of Molecular Sciences|August 6, 2020
Nutrition and PsoriasisNaoko Kanda, Toshihiko Hoashi, Hidehisa Saeki
Journal of Dermatological Science|May 22, 2013
Suppressive effects of antimycotics on thymic stromal lymphopoietin production in human keratinocytesCarren S Hau, Naoko Kanda, Shinichi Watanabe
Journal of the American Academy of Dermatology|January 29, 2025
A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patientsTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Clinical, Cosmetic and Investigational Dermatology|March 14, 2022
A Case of Darier's Disease with a Novel Missense Mutation in <i>ATP2A2</i> Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound OintmentTeppei Hagino, Hajime Nakano, Hidehisa Saeki, et al.
European Journal of Dermatology : EJD|July 22, 2009
Atypical cutaneous sarcoidosis with diffuse, indurated erythemaYayoi Tada, Naoko Kanda, Takamitsu Ohnishi, et al.
European Journal of Immunology|February 3, 2007
IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytesNaoko Kanda, Teruo Shimizu, Yayoi Tada, et al.
Journal of the American Academy of Dermatology|March 4, 2026
A 144-week real-world outcomes of upadacitinib 30 mg for atopic dermatitis in poor responders to 15 mgTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 11, 2026
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective StudyTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatological Treatment|February 2, 2024
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in JapanTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Pageof 19

Showing results (41-50 of 183) with videos related to

Sort By:
Pageof 19
International Journal of Molecular Sciences|September 25, 2019
The Roles of Sex Hormones in the Course of Atopic DermatitisNaoko Kanda, Toshihiko Hoashi, Hidehisa Saeki
International Journal of Molecular Sciences|August 6, 2020
Nutrition and PsoriasisNaoko Kanda, Toshihiko Hoashi, Hidehisa Saeki
Journal of Dermatological Science|May 22, 2013
Suppressive effects of antimycotics on thymic stromal lymphopoietin production in human keratinocytesCarren S Hau, Naoko Kanda, Shinichi Watanabe
Journal of the American Academy of Dermatology|January 29, 2025
A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patientsTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Clinical, Cosmetic and Investigational Dermatology|March 14, 2022
A Case of Darier's Disease with a Novel Missense Mutation in <i>ATP2A2</i> Successfully Treated with Calcipotriol/Betamethasone Dipropionate Two-Compound OintmentTeppei Hagino, Hajime Nakano, Hidehisa Saeki, et al.
European Journal of Dermatology : EJD|July 22, 2009
Atypical cutaneous sarcoidosis with diffuse, indurated erythemaYayoi Tada, Naoko Kanda, Takamitsu Ohnishi, et al.
European Journal of Immunology|February 3, 2007
IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytesNaoko Kanda, Teruo Shimizu, Yayoi Tada, et al.
Journal of the American Academy of Dermatology|March 4, 2026
A 144-week real-world outcomes of upadacitinib 30 mg for atopic dermatitis in poor responders to 15 mgTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 11, 2026
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective StudyTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatological Treatment|February 2, 2024
Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in JapanTeppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Pageof 19